Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.46 |
| ▸ | XDH | P47989 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15916898 | 0.87 | KDM4E (0.58) | KDM4EUSP2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL543479 | 0.87 | TDP1 (0.48) | KDM4EUSP2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL4450925 | 0.83 | PTGER4 (0.49) | DHODHKDM4ESCN8ASCN10AXDH | |
| SCHEMBL3659250 | 0.81 | SCN8A (0.49) | DHODHKDM4EUSP2ALDH1A1HPGD | |
| SCHEMBL29539667 | 0.79 | NPSR1 (0.56) | DHODHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL294263 | 0.79 | NPSR1 (0.56) | DHODHKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL15561877 | 0.79 | P4HTM (0.55) | — | |
| SCHEMBL22888657 | 0.79 | RAB9A (0.42) | DHODHALDH1A1HPGDSCN8ASCN10A | |
| SCHEMBL8628820 | 0.78 | TDP1 (0.49) | KDM4EUSP2ALDH1A1HPGDCYP2C19 | |
| SCHEMBL3721304 | 0.78 | SCN10A (0.64) | KDM4EUSP2ALDH1A1HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841483-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841483-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841483-B2 | Compositions useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2004596-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120647-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007120647-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | disclosed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | disclosed |
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238733-A1 | Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders | KCNH1, SCN5A, CACNA1A | DHODH 1254/4885KDM4E 2015/4885USP2 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.